Protopic prescribing information revised

The prescribing information for Protopic (tacrolimus) has been revised following an EMEA review of the safety and efficacy of topical calcineurin inhibitors.

Most of the changes are related to minimising the risk of developing malignancies, including cutaneous and other types of lymphomas when using Protopic to treat atopic dermatitis.

It is recommended that Protopic ointment is applied intermittently and not continuously, being discontinued when clearance occurs and re-initiated if symptoms recur.

Protopic should not be used in patients with congenital or acquired immunodeficiencies or in those being treated with immunosuppressants. Similarly, Protopic should not be applied to lesions considered to be potentially malignant or pre-malignant and care should be exercised when applying the ointment to large areas over prolonged periods.

Further information: Astellas Pharma Ltd, Lovett House, Lovett Road, Staines, Middlesex TW18 3AZ. Tel: (01784) 419615.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more